OPNT - Opiant Pharmaceuticals, Inc.
| Previous Close | 12.12 |
| Open | 12.24 |
| Bid | 11.12 x 800 |
| Ask | 15.00 x 1200 |
| Day's Range | 12.18 - 12.33 |
| 52 Week Range | 11.52 - 29.55 |
| Volume | 10,771 |
| Avg. Volume | 19,746 |
| Market Cap | 48.282M |
| Beta (3Y Monthly) | 0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.10 |
| Earnings Date | Mar 14, 2018 - Mar 19, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 38.00 |
- Yahoo Finance Video•8 days ago
Opiant CEO, creator of Narcan, weighs in on opioid overdose crisis
"This opioid crisis has become a fentanyl crisis," the CEO of Opiant Dr. Roger Crystal told Yahoo Finance's Alexis Christoforous. He then goes on to discuss what else the pharmaceutical company is doing to tackle the epidemic.
Yahoo Finance•5 days agoPharma CEO: 'This opioid crisis has become a fentanyl crisis'
The opioid crisis has become increasingly worse over the last decade and is estimated to cost the U.S. government nearly $38 billion in lost tax revenue due to employment loss.
- GlobeNewswire•12 days ago
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic (PK) data for OPNT003, nasal nalmefene containing Intravail® (dodecyl maltoside), were published online in the Journal of Pharmacology and Experimental Therapeutics and presented on Sunday, April 7, 2019, at the American Society for Pharmacology and Experimental Therapeutics 2019 Annual Meeting. The data in this manuscript, titled “Fighting Fire with Fire: Development of Intranasal Nalmefene for Treatment of Synthetic Opioid Overdose,” show that adding the absorption enhancer Intravail® to intranasal nalmefene results in very rapid and robust increases in nalmefene plasma levels with a speed of absorption comparable to intramuscular injection.
- GlobeNewswire•17 days ago
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic data of OPNT002, nasal naltrexone containing Intravail® (dodecyl maltoside), were published online in The Journal of Clinical Pharmacology.
- GlobeNewswire•19 days ago
Opiant Pharmaceuticals Announces Award of Second Tranche of Approximately $3.0 Million from National Institutes of Health Grant for Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
SANTA MONICA, Calif., April 01, 2019 -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
- GlobeNewswire•23 days ago
Opiant Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference
SANTA MONICA, Calif., March 28, 2019 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
- Zacks Small Cap Research•26 days ago
OPNT: Strong Revenue Growth for NARCAN® Nasal Spray…
On March 21, 2019, Opiant Pharmaceuticals, Inc. (OPNT) announced financial results for the fourth quarter and full year 2018. For the fourth quarter of 2018, Opiant reported total revenue of $4.8 million, with $4.4 million of revenue from the license agreement with Adapt Pharma for the sale of NARCAN® Nasal Spray. For 2018, Opiant had total revenues of $14.0 million, which included $13.3 million of revenue from the sale of NARCAN® Nasal Spray.
- GlobeNewswire•last month
Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., March 21, 2019 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
- ACCESSWIRE•last month
Opiant Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 21, 2019 / Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 21, 2019 at ...
- Benzinga•last month
The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 20) AstraZeneca plc (NYSE: AZN ) BioDelivery Sciences ...
- GlobeNewswire•last month
Opiant Pharmaceuticals to Report Fiscal 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 21
SANTA MONICA, Calif., March 18, 2019 -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
- GlobeNewswire•2 months ago
Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
-Study did not meet primary endpoint- -Company discontinuing development of OPNT001 for treatment of Bulimia Nervosa- -Focus remains on advancing lead product candidate,.
- Simply Wall St.•2 months ago
Should You Take Comfort From Insider Transactions At Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companies Read More...
- ACCESSWIRE•3 months ago
LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index
LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...
- Zacks Small Cap Research•3 months ago
OPNT: Acquires Drinabant for Acute Cannabinoid Overdose…
On December 26, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the acquisition of drinabant, a novel CB-1 receptor antagonist, for the treatment of acute cannabinoid overdose (ACO). Opiant will pay Sanofi an upfront payment of $500,000 and will be responsible for all development and commercialization activities. ACO in adults, which typically occurs from the ingestion of marijuana edibles or the use of synthetic cannabinoids, can result in anxiety, nausea, agitation, and hallucinations.
- GlobeNewswire•4 months ago
Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has entered into an exclusive global licensing agreement with Sanofi (SNY) for the development and commercialization of drinabant for the treatment of acute cannabinoid overdose (ACO). Opiant intends to develop drinabant, a cannabinoid CB-1 receptor antagonist, as an injectable for administration in an emergency department setting.
- GlobeNewswire•4 months ago
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent
SANTA MONICA, Calif., Dec. 24, 2018 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for.
- Simply Wall St.•5 months ago
Does Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) CEO Salary Reflect Performance?
Roger Crystal has been the CEO of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) since 2009. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth Read More...
- GlobeNewswire•5 months ago
New Research: Key Drivers of Growth for Huttig Building Products, Stratus Properties, Manitex International, Marathon Patent Group, Medallion Financial, and Opiant Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Insider Monkey•5 months ago
Granite Point Capital’s Returns, AUM, and Holdings
Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]
- Zacks Small Cap Research•5 months ago
OPNT: Data from Phase 2 Study of OPNT001 in Bulimia Nervosa in 1Q19…
On November 5, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced that the last patient has completed their last visit in the Phase 2 trial of OPNT001, a naloxone nasal spray, in bulimia nervosa (BN). BN is a serious and potentially life-threatening eating disorder characterized by a cycle of binge eating and purging. BN affects approximately 1-2% of the adult population with 80% of those affected being female.
- GlobeNewswire•5 months ago
Opiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., Nov. 07, 2018 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for.
- GlobeNewswire•5 months ago
Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that the Last Patient, Last Visit (LPLV) occurred on November 2, 2018, in its Phase 2 clinical trial of OPNT001, a naloxone nasal spray, for the treatment of Bulimia Nervosa. Opiant expects to report top-line data from this trial in the first quarter of 2019.
- GlobeNewswire•6 months ago
Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7th
SANTA MONICA, Calif., Nov. 01, 2018 -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for.
